Your session is about to expire
← Back to Search
Local Anesthetic
US guided ISB lateral fracture for Collarbone Fracture
N/A
Waitlist Available
Led By Paul McHardy, MD, FRCPC
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
undergoing open reduction and internal fixation of clavicle fracture (midshaft or lateral)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 hours post-op
Awards & highlights
Study Summary
The optimal analgesic peripheral nerve block (or combinations thereof) are undefined for clavicle fractures, the most frequent fracture in the human population. This goal of this study is to determine whether interscalene block (ISB), superficial cervical plexus block (SCPB), or both provide the best analgesia for lateral and midshaft clavicular fractures, respectively.
Eligible Conditions
- Collarbone Fracture
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 hours post-op
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 hours post-op
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pain measurement using NRS in PACU
Secondary outcome measures
Opioid consumption in morphine equivalence
Pain measurement using NRS at Discharge
Satisfaction using rating scale
Trial Design
6Treatment groups
Active Control
Group I: US guided ISB lateral fractureActive Control2 Interventions
Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
Group II: US guided SCPB medial fractureActive Control2 Interventions
Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
Group III: US guided ISB medial fractureActive Control2 Interventions
Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
Group IV: US guided SCPB + ISB medial fractureActive Control2 Interventions
Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
Group V: US guided SCPB + ISB lateral fractureActive Control2 Interventions
Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
Group VI: US guided SCPB lateral fractureActive Control2 Interventions
Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
657 Previous Clinical Trials
1,551,191 Total Patients Enrolled
Paul McHardy, MD, FRCPCPrincipal InvestigatorSunnybrook Health Sciences Centre
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger